Oric Pharmaceuticals CFO sells 14,000 shares

The chief financial officer’s sale was made under a Rule 10b5-1 plan adopted May 26, 2026.

Rhea-AI Filing Summary

Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised 14,000 stock options on October 20, 2026, at an exercise price of $4.36 per share, acquiring 14,000 common shares and selling 14,000 shares at a weighted average price of $13.5279 per share. The sale was made under a Rule 10b5-1 trading plan adopted May 26, 2026; sale prices ranged from $13.50 to $13.65. After the exercise, the reported position was 64,500 stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 14,000 shares ($128K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Piscitelli Dominic

Role Chief Financial Officer

Sold 14,000 shs ($189K)

Approx. gross sale proceeds $189K

Approx. exercise cost $61K

Approx. pre-tax spread $128K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	14,000	$0.00	$0.00
Exercise	Common Stock	14,000	$4.36	$61K
Sale	Common Stock F1, F2	14,000	$13.5279	$189K

Holdings After Transaction: Stock Option (right to buy) — 64,500 contracts (Direct); Common Stock — 69,828 shares (Direct)

Footnotes (2)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
2. F2. Represents the weighted average share price of an aggregate total of 14,000 shares sold in the price range of $13.50 to $13.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Stock options exercised: 14,000 options Exercise price: $4.36 per share Common shares acquired: 14,000 shares +4 more

7 metrics

Stock options exercised 14,000 options October 20, 2026

Exercise price $4.36 per share Options exercised October 20, 2026

Common shares acquired 14,000 shares October 20, 2026

Common shares sold 14,000 shares October 20, 2026

Weighted average sale price $13.5279 per share Sale on October 20, 2026

Sale price range $13.50 to $13.65 per share Range for the 14,000 shares sold

Stock options after exercise 64,500 options Reported following the October 20, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average share price, Stock Option (right to buy)

3 terms

Rule 10b5-1 trading plan regulatory

"sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average share price financial

"Represents the weighted average share price"

The weighted average share price is the average price of a stock calculated by giving each recorded trade price a weight proportional to the number of shares traded at that price (or, more generally, by the relevant share quantity for each price). It is computed as the sum of (price × shares) for all transactions divided by the total shares traded, so prices with larger volumes have a bigger effect than low-volume prices; this contrasts with a simple (unweighted) average that treats every price equally.

Stock Option (right to buy) financial

"Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORIC shares did the chief financial officer sell, and at what price?

Dominic Piscitelli sold 14,000 shares at a weighted average price of $13.5279 per share on October 20, 2026. The sale prices ranged from $13.50 to $13.65, and the sale was made under a Rule 10b5-1 trading plan adopted May 26, 2026.

How many ORIC stock options did the chief financial officer exercise?

Dominic Piscitelli exercised 14,000 stock options at an exercise price of $4.36 per share on October 20, 2026, acquiring 14,000 common shares. The reported position after the exercise was 64,500 stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 05:17 PM EDT Accepted by SEC EDGAR 10/21/2026 - 05:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piscitelli Dominic

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/20/2026		M		14,000	A	$4.36	83,828	D
Common Stock	10/20/2026		S(1)		14,000	D	$13.5279(2)	69,828	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	10/20/2026		M			14,000	07/20/2025	07/19/2032	Common Stock	14,000	$0	64,500	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.

2. Represents the weighted average share price of an aggregate total of 14,000 shares sold in the price range of $13.50 to $13.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Christian Kuhlen, attorney-in-fact	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)